4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Vogenx, Inc. (VOGX) operates in the Biotechnology industry and is headquartered in Raleigh, United States with about 4 employees. Its market capitalization is roughly $471 million. In the fiscal year ended 2025-12-31, VOGX reported $0M in revenue and ($1M) in net income.
Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total Revenue | $0M | $0M |
| Operating Income (EBIT) | ($1M) | ($2M) |
| Net Income | ($1M) | ($2M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-03-31 |
|---|---|---|
| Total Revenue | $0M | $0M |
| Operating Income (EBIT) | ($0M) | ($0M) |
| Net Income | ($0M) | ($0M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total Assets | $1M | $1M |
| Total Liabilities | $2M | $0M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive VOGX viewer.
About TickerBase · Data methodology & sources · Privacy · Terms